<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34863395</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1942-5546</ISSN><JournalIssue CitedMedium="Internet"><Volume>96</Volume><Issue>12</Issue><PubDate><Year>2021</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Mayo Clinic proceedings</Title><ISOAbbreviation>Mayo Clin Proc</ISOAbbreviation></Journal><ArticleTitle>Decline of Influenza and Respiratory Viruses With COVID-19 Public Health Measures: Alberta, Canada.</ArticleTitle><Pagination><StartPage>3042</StartPage><EndPage>3052</EndPage><MedlinePgn>3042-3052</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.mayocp.2021.09.004</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0025-6196(21)00697-2</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To determine the incidence of influenza and noninfluenza respiratory viruses (NIRVs) pre-/post-implementation of public health measures aimed to decrease coronavirus disease 2019 (COVID-19) transmission using population-based surveillance data. We hypothesized that such measures could reduce the burden of respiratory viruses (RVs) transmitting via the same routes.</AbstractText><AbstractText Label="PATIENTS AND METHODS">An interrupted time-series analysis of RV surveillance data in Alberta, Canada, from May 2017 to July 2020 was conducted. The burden of influenza and NIRVs before and after intervention initiation at week 11 was compared. The analysis was adjusted for seasonality, overdispersion, and autocorrelation.</AbstractText><AbstractText Label="RESULTS">During the study period, an average of 708 and 4056 weekly respiratory multiplex molecular panels were conducted pre-/post-intervention, respectively. We found significant reductions in test positivity rates in the postintervention period for influenza (-94.3%; 95% CI, -93.8 to 97.4%; P&lt;.001) and all NIRVs (-76.5%; 95% CI, -77.3 to -75.8%; P&lt;.001) in the crude model, and -86.2% (95% CI, -91.5 to -77.4%: P&lt;.001) and -75% (95% CI, -79.7 to -69.3%; P&lt;.001), respectively, in the adjusted models. Subanalyses for individual viruses showed significant decreases in respiratory syncytial virus, human metapneumovirus, enterovirus/rhinovirus, and parainfluenza. For non-severe acute respiratory coronavirus 2 human coronaviruses, the decline was not statistically significant after adjustment (-22.3%; 95% CI, -49.3 to&#xa0;+19%, P=.246).</AbstractText><AbstractText Label="CONCLUSION">The implementation of COVID-19 public health measures likely resulted in reduced transmission of common RVs. Although drastic lockdowns are unlikely to be required given widespread COVID-19 vaccination, targeted implementation of such measures can lower RV disease burden. Studies to evaluate relative contributions of individual interventions are warranted.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Doroshenko</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Preventive Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada; School of Public Health, University of Alberta, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Nelson</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>MacDonald</LastName><ForeName>Clayton</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology and Infection Control, Vancouver Coastal Health, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zelyas</LastName><ForeName>Nathan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada; Public Health Laboratory, Alberta Precision Laboratories, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asadi</LastName><ForeName>Leyla</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanji</LastName><ForeName>Jamil N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada; Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada; Public Health Laboratory, Alberta Precision Laboratories, Edmonton, Alberta, Canada. Electronic address: jamil.kanji@ahs.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mayo Clin Proc</MedlineTA><NlmUniqueID>0405543</NlmUniqueID><ISSNLinking>0025-6196</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000416" MajorTopicYN="N" Type="Geographic">Alberta</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003140" MajorTopicYN="Y">Communicable Disease Control</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000458" MajorTopicYN="N">organization &amp; administration</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018562" MajorTopicYN="N">Disease Transmission, Infectious</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062665" MajorTopicYN="N">Epidemiological Monitoring</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065186" MajorTopicYN="N">Interrupted Time Series Analysis</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011634" MajorTopicYN="N">Public Health</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012141" MajorTopicYN="Y">Respiratory Tract Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012621" MajorTopicYN="N">Seasons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014777" MajorTopicYN="Y">Virus Diseases</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014780" MajorTopicYN="Y">Viruses</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>5</Day><Hour>20</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>9</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34863395</ArticleId><ArticleId IdType="pmc">PMC8450272</ArticleId><ArticleId IdType="doi">10.1016/j.mayocp.2021.09.004</ArticleId><ArticleId IdType="pii">S0025-6196(21)00697-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization (WHO). Coronavirus disease (COVID-19) pandemic. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed August 24, 2020.</Citation></Reference><Reference><Citation>Government of Canada. Coronavirus disease (COVID-19): Outbreak update. Available at: https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection.html#a4. Accessed October 6, 2020.</Citation></Reference><Reference><Citation>Government of Alberta. Population statistics. Available at: https://www.alberta.ca/population-statistics.aspx. Accessed August 25, 2020.</Citation></Reference><Reference><Citation>Government of Alberta. COVID-19 info for Albertans. Available at: https://www.alberta.ca/coronavirus-info-for-albertans.aspx. Accessed October 6, 2020.</Citation></Reference><Reference><Citation>Silverstein W.K., Stroud L., Cleghorn G.E., Leis J.A. First imported case of 2019 novel coronavirus in Canada, presenting as mild pneumonia. Lancet. 2020;395(10225):734.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7134552</ArticleId><ArticleId IdType="pubmed">32061312</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanji J.N., Chichak V., Sikora C., Lee N., Tipples G., Zelyas N. First hospitalized case of laboratory-confirmed coronavirus infectious disease 2019 (COVID-19) in Alberta, Canada. J&#xa0;Assoc Med Microbiol Infect Dis Canada. 2020;5(2):98&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9602884</ArticleId><ArticleId IdType="pubmed">36338187</ArticleId></ArticleIdList></Reference><Reference><Citation>Government of Alberta. COVID-19 orders and legislation. Available at: https://www.alberta.ca/covid-19-orders-and-legislation.aspx#toc-2. Accessed August 26, 2020.</Citation></Reference><Reference><Citation>Tob&#xed;as A. Evaluation of the lockdowns for the SARS-CoV-2 epidemic in Italy and Spain after one month follow up. Sci Total Environ. 2020;725:138539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7195141</ArticleId><ArticleId IdType="pubmed">32304973</ArticleId></ArticleIdList></Reference><Reference><Citation>Valentowitsch J. Flattening the COVID-19 curve: the impact of contact restrictions on the infection curve in Germany. Gesundheitswesen. 2020;82(7):646&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7416195</ArticleId><ArticleId IdType="pubmed">32698209</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam N., Sharp S.J., Chowell G., et al. Physical distancing interventions and incidence of coronavirus disease 2019: natural experiment in 149 countries. BMJ. 2020;370:m2743.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7360923</ArticleId><ArticleId IdType="pubmed">32669358</ArticleId></ArticleIdList></Reference><Reference><Citation>Government of Canada. Respiratory Virus Detections in Canada. Available at: https://www.canada.ca/en/public-health/services/surveillance/respiratory-virus-detections-canada.html. Accessed August 28, 2020.</Citation></Reference><Reference><Citation>Alberta Health Services. Alberta Respiratory Virus Surveillance. Available at: https://public.tableau.com/profile/surveillance.reporting.ahs#!/vizhome/AlbertaHealthServicesRespiratoryVirusSurveillance/Summary. Accessed August 28, 2020.</Citation></Reference><Reference><Citation>Sakamoto H., Ishikane M., Ueda P. Seasonal influenza activity during the SARS-CoV-2 outbreak in Japan. JAMA. 2020;323(19):1969&#x2013;1971.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7149351</ArticleId><ArticleId IdType="pubmed">32275293</ArticleId></ArticleIdList></Reference><Reference><Citation>Soo R.J.J., Chiew C.J., Ma S., Pung R., Lee V. Decreased influenza incidence under COVID-19 control measures, Singapore. Emerg Infect Dis. 2020;26(8):1933&#x2013;1935.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7392467</ArticleId><ArticleId IdType="pubmed">32339092</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H., Lee H., Song K.H., et al. Impact of public health interventions on seasonal influenza activity during the SARS-CoV-2 outbreak in Korea. Clin Infect Dis. 2021;73(1):e132&#x2013;e140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7314207</ArticleId><ArticleId IdType="pubmed">32472687</ArticleId></ArticleIdList></Reference><Reference><Citation>Galvin C.J., Li Y.J., Malwade S., Syed-Abdul S. COVID-19 preventive measures showing an unintended decline in infectious diseases in Taiwan. Int J Infect Dis. 2020;98:18&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7308751</ArticleId><ArticleId IdType="pubmed">32585283</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan Nicolaides Pathology . 2020. Infectious Diseases Reports &#x2014; Respiratory viruses reports: weekly respiratory virus reports.</Citation></Reference><Reference><Citation>Zipfel C.M., Bansal S. Assessing the interactions between COVID-19 and influenza in the United States. medRxiv. 2020 doi: 10.1101/2020.03.30.20047993.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.03.30.20047993</ArticleId></ArticleIdList></Reference><Reference><Citation>Noh J.Y., Seong H., Yoon J.G., Song J.Y., Cheong H.J., Kim W.J. Social distancing against COVID-19: implication for the control of influenza. J&#xa0;Korean Med Sci. 2020;35(19):e182.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7234863</ArticleId><ArticleId IdType="pubmed">32419400</ArticleId></ArticleIdList></Reference><Reference><Citation>Cowling B.J., Ali S.T., Ng T.W.Y., et al. Impact assessment of non-pharmaceutical interventions against coronavirus disease 2019 and influenza in Hong Kong: an observational study. Lancet Public Health. 2020;5(5):e279&#x2013;e288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164922</ArticleId><ArticleId IdType="pubmed">32311320</ArticleId></ArticleIdList></Reference><Reference><Citation>GBD 2016 Lower Respiratory Infections Collaborators Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis. 2018;18(11):1191&#x2013;1210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6202443</ArticleId><ArticleId IdType="pubmed">30243584</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee N., Smith S., Zelyas N., et al. Burden of noninfluenza respiratory viral infections in adults admitted to hospital: analysis of a multiyear Canadian surveillance cohort from 2 centres. CMAJ. 2021;193(13):E439&#x2013;E446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8099164</ArticleId><ArticleId IdType="pubmed">33782171</ArticleId></ArticleIdList></Reference><Reference><Citation>Alberta Precision Laboratories (APL) - Public Health Laboratory. Laboratory bulletin: Change to community influenza testing. Available at: https://www.albertahealthservices.ca/assets/wf/lab/wf-lab-bulletin-community-influenza-testing-change.pdf. Accessed August 29, 2020.</Citation></Reference><Reference><Citation>Randhawa A.K., Fisher L.H., Greninger A.L., et al. Changes in SARS-CoV-2 positivity rate in outpatients in Seattle and Washington State, March 1&#x2013;April 16, 2020. JAMA. 2020;323(22):2334&#x2013;2336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7210505</ArticleId><ArticleId IdType="pubmed">32383728</ArticleId></ArticleIdList></Reference><Reference><Citation>Dowdy D DSG. John Hopkins Bloomberg School of Public Health Expert Insights: COVID-19 Testing: Understanding the &#x201c;Percent Positive&#x201d;. Available at: https://www.jhsph.edu/covid-19/articles/covid-19-testing-understanding-the-percent-positive.html. Accessed December 13, 2020.</Citation></Reference><Reference><Citation>Partridge E., McCleery E., Cheema R., et al. Evaluation of seasonal respiratory virus activity before and after the statewide COVID-19 shelter-in-place order in Northern California. JAMA Netw Open. 2021;4(1):e2035281.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7835714</ArticleId><ArticleId IdType="pubmed">33492377</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control (CDC). Calculating SARS-CoV-2 Laboratory Test Percent Positivity: CDC Methods and Considerations for Comparisons and Interpretation. Available at: https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/calculating-percent-positivity.html. Accessed June 27, 2021.</Citation></Reference><Reference><Citation>Park K.Y., Seo S., Han J., Park J.Y. Respiratory virus surveillance in Canada during the COVID-19 pandemic: An epidemiological analysis of the effectiveness of pandemic-related public health measures in reducing seasonal respiratory viruses test positivity. PLoS One. 2021;16(6):e0253451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8213179</ArticleId><ArticleId IdType="pubmed">34143839</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernal J.L., Cummins S., Gasparrini A. Interrupted time series regression for the evaluation of public health interventions: a tutorial. Int J Epidemiol. 2017;46(1):348&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5407170</ArticleId><ArticleId IdType="pubmed">27283160</ArticleId></ArticleIdList></Reference><Reference><Citation>Newey W., West K.D. A&#xa0;Simple, positive semi-definite, heteroskedasticity and autocorrelation consistent covariance matrix. Econometrica. 1987;55(3):703&#x2013;708.</Citation></Reference><Reference><Citation>Choe Y.J., Smit M.A., Mermel L.A. Comparison of common respiratory virus peak incidence among varying age groups in Rhode Island, 2012&#x2013;2016. JAMA Netw Open. 2020;3(5):e207041.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7221508</ArticleId><ArticleId IdType="pubmed">32401314</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsagarakis N.J., Sideri A., Makridis P., Triantafyllou A., Stamoulakatou A., Papadogeorgaki E. Age-related prevalence of common upper respiratory pathogens, based on the application of the FilmArray Respiratory panel in a tertiary hospital in Greece. Medicine (Baltimore) 2018;97(22):e10903.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6392546</ArticleId><ArticleId IdType="pubmed">29851817</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinky L., Dobrovolny H.M. SARS-CoV-2 coinfections: could influenza and the common cold be beneficial? J&#xa0;Med Virol. 2020;92(11):2623&#x2013;2630.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7300957</ArticleId><ArticleId IdType="pubmed">32557776</ArticleId></ArticleIdList></Reference><Reference><Citation>Marriott D., Beresford R., Mirdad F., et al. Concomitant marked decline in prevalence of SARS-CoV-2 and other respiratory viruses among symptomatic patients following public health interventions in Australia: data from St Vincent's Hospital and associated screening clinics, Sydney, NSW. Clin Infect Dis. 2021;72(10):e649&#x2013;e651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7499558</ArticleId><ArticleId IdType="pubmed">32841316</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei H., Xu M., Wang X., et al. Nonpharmaceutical interventions used to control COVID-19 reduced seasonal influenza transmission in China. J&#xa0;Infect Dis. 2020;222(11):1780&#x2013;1783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7499620</ArticleId><ArticleId IdType="pubmed">32898256</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo S.C., Shih S.M., Chien L.H., Hsiung C.A. Collateral benefit of COVID-19 control measures on influenza activity, Taiwan. Emerg Infect Dis. 2020;26(8):1928&#x2013;1930.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7392415</ArticleId><ArticleId IdType="pubmed">32339091</ArticleId></ArticleIdList></Reference><Reference><Citation>Hills T., Kearns N., Kearns C., Beasley R. Influenza control during the COVID-19 pandemic. Lancet. 2020;396(10623):1633&#x2013;1634.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7581384</ArticleId><ArticleId IdType="pubmed">33228919</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan S.G., Carlson S., Cheng A.C., et al. Where has all the influenza gone? The impact of COVID-19 on the circulation of influenza and other respiratory viruses, Australia, March to September 2020. Euro Surveill. 2020;25(47):2001847.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7693168</ArticleId><ArticleId IdType="pubmed">33243355</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo J.Y., Tsang T.H., Leung Y.H., Yeung E.Y., Wu T., Lim W.W. Respiratory infections during SARS outbreak, Hong Kong, 2003. Emerg Infect Dis. 2005;11(11):1738&#x2013;1741.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3367357</ArticleId><ArticleId IdType="pubmed">16318726</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker R.E., Park S.W., Yang W., Vecchi G.A., Metcalf C.J.E., Grenfell B.T. The impact of COVID-19 nonpharmaceutical interventions on the future dynamics of endemic infections. Proc Natl Acad Sci U S A. 2020;117(48):30547&#x2013;30553.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7720203</ArticleId><ArticleId IdType="pubmed">33168723</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodjat P., Christensen P.A., Subedi S., Bernard D.W., Olsen R.J., Long S.W. The rapid reemergence of seasonal respiratory viruses in Houston, Texas, after relaxing COVID-19 restrictions. microbiology spectrum. 2021;9(2) doi: 10.1128/Spectrum.00430-21. ee00430-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/Spectrum.00430-21</ArticleId><ArticleId IdType="pmc">PMC8557899</ArticleId><ArticleId IdType="pubmed">34494861</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrick D.M., Petric M., Skowronski D.M., et al. An outbreak of human coronavirus OC43 infection and serological cross-reactivity with SARS coronavirus. Can J Infect Dis Med Microbiol. 2006;17(6):330&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2095096</ArticleId><ArticleId IdType="pubmed">18382647</ArticleId></ArticleIdList></Reference><Reference><Citation>Monto A.S., DeJonge P.M., Callear A.P., et al. Coronavirus occurrence and transmission over 8 years in the HIVE cohort of households in Michigan. J&#xa0;Infect Dis. 2020;222(1):9&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184402</ArticleId><ArticleId IdType="pubmed">32246136</ArticleId></ArticleIdList></Reference><Reference><Citation>Nickbakhsh S., Ho A., Marques D.F.P., McMenamin J., Gunson R.N., Murcia P.R. Epidemiology of seasonal coronaviruses: establishing the context for the emergence of coronavirus disease 2019. J&#xa0;Infect Dis. 2020;222(1):17&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184404</ArticleId><ArticleId IdType="pubmed">32296837</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control (CDC). The National Respiratory and Enteric Virus Surveillance System (NREVSS): National Trends for Common Human Coronaviruses. Available at: https://www.cdc.gov/surveillance/nrevss/coronavirus/natl-trends.html. Accessed June 30, 2021.</Citation></Reference><Reference><Citation>Government of Canada. Respiratory Virus Detections in Canada. Available at: https://www.canada.ca/en/public-health/services/surveillance/respiratory-virus-detections-canada.html. Accessed June 29, 2021.</Citation></Reference><Reference><Citation>Hospitaux Universitaires Geneve. Surveillance of seasonal influenza, SARS-CoV-2 and other respiratory viruses in Switzerland. Available at: https://www.hug.ch/en/virology-laboratory/surveillance-seasonal-influenza-sars-cov-2-and-other-respiratory-viruses. Accessed June 29, 2021.</Citation></Reference><Reference><Citation>Poole S., Brendish N.J., Tanner A.R., Clark T.W. Physical distancing in schools for SARS-CoV-2 and the resurgence of rhinovirus. Lancet Respir Med. 2020;8(12):e92&#x2013;e93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7581315</ArticleId><ArticleId IdType="pubmed">33289636</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall N.C., Kariyawasam R.M., Zelyas N., Kanji J.N., Diggle M.A. Broad respiratory testing to identify SARS-CoV-2 viral co-circulation and inform diagnostic stewardship in the COVID-19 pandemic. Virol J. 2021;18(1):93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8087885</ArticleId><ArticleId IdType="pubmed">33933115</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee N., Smith S., Zelyas N., Zelyas N., et al. Burden of noninfluenza respiratory viral infections in adults admitted to hospital: analysis of a multiyear Canadian surveillance cohort from 2 centres. Canadian Medical Association Journal. 2021;193(13):E439&#x2013;E446. doi: 10.1503/cmaj.201748.</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.201748</ArticleId><ArticleId IdType="pmc">PMC8099164</ArticleId><ArticleId IdType="pubmed">33782171</ArticleId></ArticleIdList></Reference><Reference><Citation>Government of Alberta. Influenza - the flu. Available at: https://www.alberta.ca/influenza-the-flu.aspx. Accessed September 14, 2020.</Citation></Reference><Reference><Citation>Prime Minister of Canada. Prime Minister announces new actions under Canada's COVID-19 response (March 16, 2020). Available at: https://pm.gc.ca/en/news/news-releases/2020/03/16/prime-minister-announces-new-actions-under-canadas-covid-19-response. Accessed June 29, 2021.</Citation></Reference><Reference><Citation>Canadian Public Health Association. Review of Canada's Initial Response to the COVID-19 Pandemic. Available at: https://www.cpha.ca/review-canadas-initial-response-covid-19-pandemic. Accessed June 29, 2021.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>